Clinical Data Data backs GSK’s ovarian cancer blockbuster hopes PharmaphorumGSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
